Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: Results of a phase II and pharmacologic study

Anti-Cancer Drugs

Volumn 18, Issue 2, 2007, Pages 211-218

  Dumez, Herlinde ^a   Martens, Marc ^b   Selleslach, Johan ^a   Guetens, Gunter ^a   De Boeck, Gert ^a   Aerts, Rita ^a   De Bruijn, Ernst A ^a   Maes, Robert A ^c   Van Oosterom, Allan T ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Sint Elisabethziekenhuis Turnhout   (Belgium)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Docetaxel; Erythrocyte; Gemcitabine; Phase II; Transitional cell carcinoma

Indexed keywords

DOCETAXEL; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG TOLERABILITY; ERYTHROCYTE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART FAILURE; HUMAN; HYPOTENSION; INFECTION; LUNG TOXICITY; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CELL SURVIVAL; DEOXYCYTIDINE; ERYTHROCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; TAXOIDS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33845686332     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328010ee5c     Document Type: Article

References (26)

1. von der Maase H. Current and future perspectives in advanced bladder cancer: is there a new standard? Semin Oncol 2002; 29:3-14.
2. Hussain M, Vaishampayan U, Smith DC. Novel gemcitabine-containing triplets in the management of urothelial cancer. Semin Oncol 2002; 29:20-24.
3. Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Albanell J, et al. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer. Eur J Cancer 2000; 36:17-25.
4. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991; 51:6110-6117.
5. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs 1995; 6:7-13.
6. Ringel I, Orwitz SB. Studies with RP-56976 (Taxotere): a semi-synthetic analogue of Taxol. J Natl Cancer Inst 1991; 83:288-291.
7. Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, van Oosterom AT, et al. The impact of drug-administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumours. Anticancer Drugs 2002; 13:583-593.
8. Driessen O, Highley MS, Harper PG, Maes RA, de Bruijn EA. Description of an instrument for separation of red cells from plasma and measurement of red cell volume. Clin Biochem 1994; 27:195-196.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. EORTC, NCI of the United States, NCI of Canada. J Natl Cancer Inst 2000; 92:205-216.
10. Dreicer R, Manola J, Schneider DJ, Schwerkoske JF, George CS, Roth BJ, et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003; 97:2743-2747.
11. Gitlitz BJ, Baker C, Chapman Y, Allen HJ, Bosserman LD, Patel R, et al. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 2003; 98:1863-1869.
12. Meluch AA, Greco FA, Burris HA 3rd, O'Rourke T, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001; 19:3018-3024.
13. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every 2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92:2993-2998.
14. Pectasides D, Glotsos J, Bountouroglou N, Kouloubinis A, Mitakidis N, Karvounis N, et al. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Ann Oncol 2002; 13:243-250.
15. Fumoleau P. Gemcitabine combined with docetaxel in metastatic breast cancer. Semin Oncol 2003; 30:15-18.
16. Yardley DA. Gemcitabine and taxanes as a new standard of care in breast cancer. Clin Breast Cancer Suppl 2004; 433:S107-S112.
17. Georgoulias VA. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer. Oncology 2001; 15:18-24.
18. Alexopoulos A, Tryfonopoulos D, Karamouzis MV, Gerasimidis G, Karydas I, Kandilis K, et al. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer. Ann Oncol 2004; 15:95-99.
19. Natale RB. Gemcitabine and taxane combinations in non small-cell lung cancer. Clin Lung Cancer 2000; 2:S15-S21.
20. Georgoulias V. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer. Curr Med Chem 2002; 9:869-877.
21. Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003; 65:218-223.
22. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94:97-103.
23. Sherman WH, Fine RL. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology 2001; 60:316-321.
24. Fountzilas G, Stathopoulos G, Nicolaides C, Kalogera-Fountzila A, Kalofonos H, Nikolaou A, et al. Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10:475-478.
25. Hinton S, Catalano P, Einhorn LH, Loehrer PJ Sr, Kuzel T, Vaughn D, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002; 20:1859-1863.
26. Dumez H, Guetens G, De Boeck G, Highley MS, de Bruijn EA, van Oosterom AT, et al. In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender. Anticancer Drugs 2005; 16:885-891.